Lineage Cell Therapeutics (LCTX): Applying Cell Therapy to Areas of Unmet Medical Need

Time: 9:00 am
day: Day Two

Details:

  • Examine OpRegen: An RPE transplant therapy in a Phase 1/2a trial for the treatment of dry-AMD with geographic atrophy
  • Explore OPC1: An oligodendrocyte progenitor therapy for acute spinal cord injuries with Orphan and RMAT designations; phase 1 completed
  • Discuss VAC2: An allogeneic cancer immunotherapy of antigenpresenting dendritic cells currently in a Phase 1 for oncology

Speakers:

Brian Culley
Brian Culley

Mr. Culley joined Lineage as CEO in September 2018.  Prior to joining Lineage, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he was responsible for the management of the company. Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc.…Read more